A Phase 2 interventional study of LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU in Non-Hodgkin's Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:
2,043 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 309 are open to participants now.
This study's enrollment of 17 is below the median of 40 across 1,744 interventional studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,957 studies on the registry; 323 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 68 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-Hodgkin's Lymphoma stages III, IV, IVA with
Exclusion Criteria:
Drug: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
LSA4 intervention includes three phases: induction, consolidation and maintenance
Complete Remission
The number of patients who achieved a complete remission as a result of treatment
Time frame: 330 Days
| Milestone | All Patients |
|---|---|
| Started | 17 |
| Completed | 17 |
| Not completed | 0 |
The number of patients who achieved a complete remission as a result of treatment
| participants | All Patients |
|---|---|
| Complete Remission | 10 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Patients | — | 1/17 (5.9%) | 17/17 (100%) |
| Event | All Patients |
|---|---|
| Ruptured Necrotic TumorCardiac disorders | 1/17 |
| Event | All Patients |
|---|---|
| Hematological ToxicityBlood and lymphatic system disorders | 17/17 |
| Hepatic ToxicityRenal and urinary disorders | 17/17 |
| Age, Customized(years) | All Patients |
|---|---|
| Median Age | 12 (2 to 19) |
| Sex: Female, Male(Participants) | All Patients |
|---|---|
| Female | 5 |
| Male | 12 |
The record gives a start of May 1990, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 7 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →